{
  "extraction_metadata": {
    "timestamp": "2025-10-02T18:12:25.834364",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "temperature": 0.1
  },
  "outcomes_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "progression-free survival (blinded, independent central review), overall survival (time from randomisation to death from any cause), symptomatology, health status, health-related quality of life, side effects, EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C",
      "ChunksUsed": 10,
      "ContextTokens": 2233
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "progression-free survival (PFS), progression-free survival (investigator-assessed), progression-free survival (RECIST), overall survival (OS), event-free survival, time to progression (TTP), time to next treatment (TTNT), response rates, objective response rate (ORR), disease control rate, treatment duration, progression after next line of therapy (PFS2), adverse events, adverse events (CTCAE v5.0), adverse events (CTCAE v4.03), EORTC QLQ-C30, EQ-5D-5L",
      "ChunksUsed": 10,
      "ContextTokens": 2352
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "overall survival, progression-free survival, objective response rate (RECIST 1.1), health-related quality of life, visual analogue scale, utility decrement per cycle of treatment, adverse events, treatment-related disutility for intravenous administration",
      "ChunksUsed": 10,
      "ContextTokens": 2081
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "progression-free survival (independent, blinded review panel; RECIST 1.1), objective response rate (independent review committee; RECIST 1.1), overall survival (time from randomization to death from any cause), duration of response (RECIST 1.1), disease control rate (proportion with complete, partial, or stable disease for ≥5 weeks), time to response (from treatment initiation to first complete or partial response), serious adverse events, serious undesirable effects, adverse events (general)",
      "ChunksUsed": 10,
      "ContextTokens": 2273
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "Outcomes": "",
      "ChunksUsed": 6,
      "ContextTokens": 1644
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), diarrhoea, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), fatigue, fever, peripheral oedema, shortness of breath, cough, vomiting, decreased appetite, constipation, anaemia, alopecia, neutropenia, increased asparagine aminotransferase, chest pain, pneumonia, adverse events (general), treatment-related adverse events, treatment-related adverse reactions grade ≥3, treatment-associated adverse experiences leading to discontinuation of therapy, dose modification-related adverse drug reactions, treatment-associated adverse events resulting in death, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer Module (EORTC QLQ-LC13), economic outcomes (incremental cost-effectiveness ratio, ICUR), budgetary impact analysis",
      "ChunksUsed": 10,
      "ContextTokens": 2372
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, time to progression, time to next treatment, duration of treatment, overall survival (OS), progression-free survival (PFS), eventless survival, adverse events (CTCAE v5.0), serious adverse events (Grade 3-4), dropout rate, mortality-related toxicity, quality of life, overall health status, physical functioning",
      "ChunksUsed": 10,
      "ContextTokens": 2667
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "progression-free survival (PFS), overall survival (OS), health-related quality of life measured by time to death, quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY achieved)",
      "ChunksUsed": 10,
      "ContextTokens": 2298
    }
  }
}